東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Histone deacetylase inhibitors = epi...

Ganai, Shabir Ahmad.

FindBook

Google Book

Amazon

博客來

Histone deacetylase inhibitors = epidrugs for neurological disorders /

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Histone deacetylase inhibitors/ by Shabir Ahmad Ganai.
其他題名:	epidrugs for neurological disorders /
作者:	Ganai, Shabir Ahmad.
出版者:	Singapore :Springer Singapore : : 2019.,
面頁冊數:	xvii, 93 p. :ill., digital ;24 cm.
內容註:	Chapter 1. Role of Epigenetics in neurological diseases -- Chapter 2. Epigenetic enzymes and the drawbacks of conventional therapeutic regimens -- Chapter 3. Distinct classes of HDACs -- Chapter 4. HDAC implications in neurological diseases -- Chapter 5. HDAC inhibitors and their structurally distinct groups -- Chapter 6. HDAC inhibitors as novel therapeutic option against therapeutically challenging neurological disorders -- Chapter 7. Current Challenges with HDAC inhibitor based therapeutic intervention against neurological maladies -- Chapter 8. Escalating need of isoform selective inhibitors for enhanced therapeutic efficacy -- Chapter 9. Combinatorial therapeutic regimens using HDAC inhibitors in conjunction with conventional therapeutic agents -- Chapter 10. Future directions of epigenetic research in tackling neurological complications.
Contained By:	Springer Nature eBook
標題:	Histone deacetylase - Inhibitors. -
電子資源:	https://doi.org/10.1007/978-981-13-8019-8
ISBN:	9789811380198

Histone deacetylase inhibitors = epidrugs for neurological disorders /
Ganai, Shabir Ahmad.

Histone deacetylase inhibitorsepidrugs for neurological disorders /[electronic resource] :by Shabir Ahmad Ganai. - Singapore :Springer Singapore :2019. - xvii, 93 p. :ill., digital ;24 cm.

Chapter 1. Role of Epigenetics in neurological diseases -- Chapter 2. Epigenetic enzymes and the drawbacks of conventional therapeutic regimens -- Chapter 3. Distinct classes of HDACs -- Chapter 4. HDAC implications in neurological diseases -- Chapter 5. HDAC inhibitors and their structurally distinct groups -- Chapter 6. HDAC inhibitors as novel therapeutic option against therapeutically challenging neurological disorders -- Chapter 7. Current Challenges with HDAC inhibitor based therapeutic intervention against neurological maladies -- Chapter 8. Escalating need of isoform selective inhibitors for enhanced therapeutic efficacy -- Chapter 9. Combinatorial therapeutic regimens using HDAC inhibitors in conjunction with conventional therapeutic agents -- Chapter 10. Future directions of epigenetic research in tackling neurological complications.

This book provides an outline of epigenetics as a whole, while also specifically examining a range of epigenetic players, including histone acetyl transferases (HATs) and histone deacetylases (HDACs) It chiefly focuses on the emerging targets of HDACs and their implications for various neurological disorders, while also discussing the drawbacks of current therapeutic strategies, the classification of HDAC inhibitors, and their promising effects in connection with specific neurological disorders. The book explores the potential use of these inhibitors as novel therapeutic agents, considers the current challenges involved in using them to tackle neurological complications, and offers a novel solution by designing isoform-selective inhibitors and employing combinatorial therapeutic strategies. Its final section, which explores future directions, elaborates on the possibility of enhancing HDAC inhibitors' therapeutic efficacy against various neurological complications.

ISBN: 9789811380198

Standard No.: 10.1007/978-981-13-8019-8doiSubjects--Topical Terms:

3501831
Histone deacetylase
--Inhibitors.

LC Class. No.: QC552.H5 / G363 2019

Dewey Class. No.: 612.8

Histone deacetylase inhibitors = epidrugs for neurological disorders /
LDR:02845nmm a2200325 a 4500 001 2242549
003 DE-He213
005 20200902170201.0
006 m d
007 cr nn 008maaau
008 211207s2019 si s 0 eng d
020 $a 9789811380198 $q (electronic bk.)
020 $a 9789811380181 $q (paper)
024 7 $a 10.1007/978-981-13-8019-8 $2 doi
035 $a 978-981-13-8019-8
040 $a GP $c GP
041 0 $a eng
050 4 $a QC552.H5 $b G363 2019
072 7 $a PSAN $2 bicssc
072 7 $a MED057000 $2 bisacsh
072 7 $a PSAN $2 thema
082 0 4 $a 612.8 $2 23
090 $a QC552.H5 $b G195 2019
100 1 $a Ganai, Shabir Ahmad. $3 3501830
245 1 0 $a Histone deacetylase inhibitors $h [electronic resource] : $b epidrugs for neurological disorders / $c by Shabir Ahmad Ganai.
260 $a Singapore : $b Springer Singapore : $b Imprint: Springer, $c 2019.
300 $a xvii, 93 p. : $b ill., digital ; $c 24 cm.
505 0 $a Chapter 1. Role of Epigenetics in neurological diseases -- Chapter 2. Epigenetic enzymes and the drawbacks of conventional therapeutic regimens -- Chapter 3. Distinct classes of HDACs -- Chapter 4. HDAC implications in neurological diseases -- Chapter 5. HDAC inhibitors and their structurally distinct groups -- Chapter 6. HDAC inhibitors as novel therapeutic option against therapeutically challenging neurological disorders -- Chapter 7. Current Challenges with HDAC inhibitor based therapeutic intervention against neurological maladies -- Chapter 8. Escalating need of isoform selective inhibitors for enhanced therapeutic efficacy -- Chapter 9. Combinatorial therapeutic regimens using HDAC inhibitors in conjunction with conventional therapeutic agents -- Chapter 10. Future directions of epigenetic research in tackling neurological complications.
520 $a This book provides an outline of epigenetics as a whole, while also specifically examining a range of epigenetic players, including histone acetyl transferases (HATs) and histone deacetylases (HDACs) It chiefly focuses on the emerging targets of HDACs and their implications for various neurological disorders, while also discussing the drawbacks of current therapeutic strategies, the classification of HDAC inhibitors, and their promising effects in connection with specific neurological disorders. The book explores the potential use of these inhibitors as novel therapeutic agents, considers the current challenges involved in using them to tackle neurological complications, and offers a novel solution by designing isoform-selective inhibitors and employing combinatorial therapeutic strategies. Its final section, which explores future directions, elaborates on the possibility of enhancing HDAC inhibitors' therapeutic efficacy against various neurological complications.
650 0 $a Histone deacetylase $x Inhibitors. $3 3501831
650 1 4 $a Neurosciences. $3 588700
650 2 4 $a Pharmacology/Toxicology. $3 890953
650 2 4 $a Genetics and Genomics. $3 3385208
650 2 4 $a Protein Science. $3 1067276
650 2 4 $a Posttranslational Modification. $3 2055482
710 2 $a SpringerLink (Online service) $3 836513
773 0 $t Springer Nature eBook
856 4 0 $u https://doi.org/10.1007/978-981-13-8019-8
950 $a Biomedical and Life Sciences (SpringerNature-11642)